Cabozantinib Is More Effective Than Erlotinib in EGFR –Wild-Type NSCLC

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2016-220
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

The Orl Rat Is More Responsive to Methacholine Challenge Than Wild Type

Pulmonary Pharmacology and Therapeutics
BiochemistryMedicinePulmonaryRespiratory MedicinePharmacology
2014English

Dextransucrase From the Mutant of Pediococcus Pentosaceus (PPm) Is More Stable Than the Wild Type

3 Biotech
AgriculturalBiotechnologyEnvironmental ScienceBiological Sciences
2011English

Onyx Is More Effective Than Coil Embolization for the Treatment of Type II Endoleaks

Journal of Vascular Surgery
SurgeryCardiovascular MedicineCardiology
2019English

Domperidone Is More Effective Than Cisapride in Children With Diabetic Gastroparesis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2002English

Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Vitamin D Deficiency Is More Common in Type 2 Than in Type 1 Diabetes

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy